Search research articles
Contact Us
Filters
Showing results (131-140 of 168) with videos related to
Page
of 17
Sort By:
Leukemia & Lymphoma
|
March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults
Philip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
Haematologica
|
December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
Amir T Fathi, Seth A Wander, Traci M Blonquist, et al.
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances
|
July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Cancer
|
September 30, 2017
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation
Amir T Fathi, Traci M Blonquist, Daniela Hernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Blood
|
December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenib
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 168) with videos related to
Sort By:
Page
of 17
Leukemia & Lymphoma
|
March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults
Philip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
Haematologica
|
December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
Amir T Fathi, Seth A Wander, Traci M Blonquist, et al.
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances
|
July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Cancer
|
September 30, 2017
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation
Amir T Fathi, Traci M Blonquist, Daniela Hernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Blood
|
December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenib
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Page
of 17